2938955-39-4
Chemical Structure
Saralasin TFA
Synonym(s): [Sar1,Ala8] Angiotensin II TFA
- CAS No.: 2938955-39-4
- Formula:C44H66F3N13O12
- Molecular Weight:1026.07
IUPAC Name: methylglycyl-L-arginyl-L-valyl-L-tyrosyl-L-valyl-L-histidyl-L-prolyl-L-alanine compound with 2,2,2-trifluoroacetic acid (1:1)
InChIKey: MSJJUBUOJZCFIK-LYHTUURTSA-N
SMILES: C[C@H](NC([C@H]1N(CCC1)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC)=O)CCCNC(N)=N)=O)C(C)C)=O)CC2=CC=C(O)C=C2)=O)C(C)C)=O)CC3=CNC=N3)=O)=O)C(O)=O.OC(C(F)(F)F)=O
Biological Activity: Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension[1][3][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Saralasin TFA | 99.37% | Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. P Schelling, et al. Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol. 1979 Mar;98(3):503-13. [Content Brief]
- [3]. Maziar Mohammad Akhavan, et al. A non-radioactive method for angiotensin II receptor binding studies using the rat liver. J Pharmacol Toxicol Methods. 2006 May-Jun;53(3):206-14. [Content Brief]
- [6]. Campbell WB, et al. Saralasin-induced renin release: its blockade by prostaglandin synthesis inhibitors in the conscious rat. Hypertension. 1979;1(6):637‐642. [Content Brief]
